Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 14 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients with HER2-altered Tumours, Including NSCLC EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab to Unresectable or Advanced HCC ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March MOST POPULAR A College Senior vs. A Global Pandemic September 30, 2020 確診癌症後患者應如何面對悲傷 July 7, 2020 20.° Aniversario de Cancer.Net: Celebramos Nuestra Misión de Brindar Información Confiable... November 16, 2022 Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with... November 22, 2024 Load more HOT NEWS Predicting future breast cancer with precision Kid Friendly Meals ESMO 2024 Press Conference Gift Giving During a Pandemic
